Cutaneous Horn Removal in India and UAE | Complete Patient Guide

• IDEAL SURGICAL CANDIDATES:

• Adults with a clinically apparent keratin horn, particularly lesions growing on the scalp, ear helix, nose, lips, dorsal hands, forearms, or trunk in individuals with significant cumulative sun exposure

• Patients with a horn base that is erythematous, ulcerated, indurated, or friable — features that mandate urgent excisional biopsy rather than watchful waiting

• Immunocompromised patients (solid-organ transplant recipients, HIV-positive individuals on antiretrovirals, patients on long-term systemic immunosuppressants) given the markedly elevated risk of malignant base pathology

• Patients with a prior personal or family history of non-melanoma skin cancer or a known diagnosis of actinic keratosis in the peri-lesional skin

• Individuals seeking cosmetic removal of a confirmed benign cutaneous horn causing functional impairment (e.g., pressure, trauma, psychological distress)

• Paediatric patients with HPV-associated filiform warts that clinically mimic small cutaneous horns (managed under local or general anaesthesia depending on age and lesion burden)

• REQUIRED PRE-PROCEDURAL ASSESSMENTS:

• High-resolution dermoscopy to evaluate the base vascular pattern (hairpin vessels, irregular dotted vessels, or ulceration suggest SCC)

• Reflectance confocal microscopy (RCM) — where available at tertiary centres — for non-invasive cellular-level assessment of the base

• Routine bloods: CBC, coagulation screen (PT/INR/aPTT), random blood glucose, and HbA1c in diabetic patients (wound healing risk stratification)

• Hepatitis B/C and HIV serology (standard pre-operative infectious disease screen)

• Skin phototype and UV exposure history documentation

• For clinically advanced or recurrent lesions: high-resolution ultrasound (20–50 MHz) of the lesion and regional lymph node basins; CT of neck/chest/abdomen if nodal metastasis is suspected

• Pathergy test and autoimmune panel if the differential diagnosis includes pyoderma gangrenosum or other neutrophilic dermatoses mimicking a horn-like lesion

• CONTRAINDICATIONS & RELATIVE CAUTIONS:

• Active local skin infection at the surgical site (procedure must be deferred until infection is fully treated)

• Uncontrolled coagulopathy or therapeutic anticoagulation that cannot be safely bridged (warfarin, DOACs — requires haematology liaison)

• Uncontrolled diabetes mellitus (HbA1c >9% associated with impaired wound healing; optimise prior to elective excision)

• Keloid or hypertrophic scar diathesis (relative contraindication; counsel patient on scar outcomes and consider adjuvant intralesional triamcinolone post-excision)

• Allergy to local anaesthetic agents (lidocaine/prilocaine) — require anaesthetic review for safe alternative

• Pregnancy: elective excision deferred to post-partum unless lesion is rapidly growing or malignancy strongly suspected

EXCISIONAL TECHNIQUES — STANDARD TO ADVANCED:

1. SIMPLE ELLIPTICAL EXCISION (Standard Approach)

The workhorse technique for the majority of cutaneous horns. The surgeon marks a fusiform (elliptical) excision encompassing the horn base with a minimum lateral margin of 2–4 mm (benign/AK base) or 5–10 mm (confirmed or highly suspected SCC). Excision is carried to mid-dermis or sub-dermal fat depending on the depth of the base lesion. Primary layered closure is achieved with deep absorbable sutures (Vicryl 3-0/4-0) and superficial non-absorbable monofilament (Prolene or Ethilon 4-0/5-0) or subcuticular absorbable closure. The entire specimen — horn and base together — is submitted for bread-loaf histopathology. Performed under local infiltration anaesthesia (1–2% lidocaine with 1:100,000 epinephrine) as an outpatient procedure. Estimated operative time: 15–45 minutes.

2. MOHS MICROGRAPHIC SURGERY (MMS) — Gold Standard for Malignant Base SCC

When final histopathology confirms invasive SCC at the base, or when the lesion is in a cosmetically or functionally critical location (periocular, nasal, auricular, lip), MMS offers the highest cure rate (>99% for primary SCC) with maximal tissue conservation. The procedure involves sequential horizontal tissue layers removed under direct surgeon control, with 100% peripheral and deep margin mapping using frozen sections processed en-face. Each 'stage' takes approximately 45–60 minutes of processing; most lesions are cleared in 1–3 stages (day procedure). Reconstruction — whether primary closure, local flap (rhomboid, bilobed, advancement), or full-thickness skin graft — is planned based on the final defect geometry. Mohs-trained surgeons operate at select JCI-accredited centres in Mumbai, Delhi, Hyderabad, Dubai, and Abu Dhabi.

3. SHAVE EXCISION + ELECTRODESICCATION (Limited Diagnostic/Cosmetic Role)

Reserved only for clinically unequivocal benign lesions (e.g., a small filiform wart-based horn in a young patient with no risk factors). A curette or scalpel blade is used to shave the horn flush with the skin surface, followed by electrodesiccation of the base using a monopolar electrosurgical unit (Hyfrecator or radiofrequency device) at 1–3 watts. Healing is by secondary intention. Not appropriate when SCC is in the differential, as deep-margin assessment is impossible.

4. CO₂ LASER ABLATION

Fractional or continuous-wave CO₂ laser (10,600 nm wavelength) can vaporise small, confirmed-benign cutaneous horns with excellent cosmesis in skin types I–III. The primary limitation is tissue destruction without specimen retrieval, making histopathology impossible. Therefore, it is used only after prior punch biopsy of the base has confirmed a benign aetiology. Effective for HPV-associated horn variants; requires protective eyewear and smoke evacuation. Available at select laser dermatology units in Delhi, Mumbai, Bengaluru, Dubai, and Abu Dhabi.

5. CRYOSURGERY WITH LIQUID NITROGEN

Liquid nitrogen spray (−196°C) applied in double freeze-thaw cycles (10–30 seconds per cycle) can treat small, confirmed-benign horn-base lesions such as actinic keratosis. Tissue temperatures at the advancing ice-ball front reach −50°C, inducing intracellular ice crystal formation and cell membrane rupture. Like laser ablation, tissue is not retrievable for histopathology; pre-procedure biopsy is mandatory if SCC cannot be excluded clinically and dermoscopically.

6. SYSTEMIC AND TOPICAL ADJUNCTS (Post-Excision SCC Base Management)

Where invasive SCC is confirmed at the base and surgical margins are involved or re-excision is not feasible:

• Topical imiquimod 5% cream (TLR-7 agonist; immune-modulation) for superficial SCC in situ — 5 days per week for 6–16 weeks

• 5-fluorouracil (5-FU) 5% cream for field cancerisation in peri-lesional actinic keratosis

• Cemiplimab (anti-PD-1 monoclonal antibody; Libtayo®) — FDA/EMA-approved for locally advanced or metastatic cutaneous SCC not amenable to surgery or radiotherapy; available at oncology centres affiliated with GAF Healthcare partner hospitals

• Adjuvant radiotherapy (external beam, 50–66 Gy in 25–33 fractions) for high-risk SCC with perineural invasion, positive margins post-re-excision, or nodal disease

7. SENTINEL LYMPH NODE BIOPSY (SLNB)

Considered for cutaneous SCC at the horn base with Breslow depth >2 mm, Clark level IV/V, poor differentiation, or lymphovascular invasion — consistent with emerging NCCN high-risk criteria. Technetium-99m nanocolloid lymphoscintigraphy maps the sentinel node preoperatively; SLNB is performed under general anaesthesia concurrently with wide local excision.

PRE-ARRIVAL (2–4 WEEKS BEFORE TRAVEL):

• GAF Healthcare patient coordinators review uploaded clinical photographs, prior biopsy reports, and medical history to establish provisional risk category (benign vs. suspected malignant base)

• Remote dermoscopy image review by the treating surgeon where high-resolution photographs are available

• Pre-procedure blood tests and any imaging requested remotely, with results forwarded to the surgical team

• e-Medical Visa application supported by GAF Healthcare (India) or visit visa/visa-on-arrival arrangement (UAE)

• Flight and accommodation booked; airport transfer and hospital admission formalities coordinated

DAY 1 — ARRIVAL AND CONSULTATION:

• Airport pickup by GAF Healthcare liaison; hotel check-in or hospital admission depending on clinical complexity

• In-person consultation with board-certified plastic surgeon or Mohs-trained dermatosurgeon: clinical examination, dermoscopy, consent, and anaesthetic review

• Pre-operative bloods and any additional imaging completed same day at the hospital

• Nil-by-mouth (NBM) instructions issued if general/sedation anaesthesia is planned (rare for this procedure; most performed under local anaesthesia with no NBM requirement)

DAY 2 (OR DAY 1 AFTERNOON) — THE PROCEDURE:

• Patient positioned and surgical site marked under dermatoscopic guidance

• Local infiltration anaesthesia administered (lidocaine 1–2% with 1:100,000 adrenaline; onset 3–5 minutes; field lasts 45–90 minutes)

• Elliptical excision performed; specimen oriented with sutures or ink and submitted to pathology in formalin

• Wound closed in layers; non-adherent paraffin gauze dressing applied

• Operative time: 20–60 minutes for standard excision; 3–6 hours total (including staged processing) for Mohs surgery

• Patient discharged 1–3 hours post-procedure with wound care instructions, oral analgesics (paracetamol ± ibuprofen; opioids rarely required), and topical mupirocin antibiotic ointment

DAY 3–7 — EARLY POST-OPERATIVE PHASE:

• Wound checked at 48–72 hours by nursing staff or GAF Healthcare's on-call coordinator

• Patient advised to keep the wound clean and dry; gentle cleansing with chlorhexidine solution and reapplication of non-adherent dressing

• Mild swelling and bruising at the excision site normalises by Day 4–5

• Sutures remain in place (non-absorbable monofilament) — no early removal

• Provisional histopathology report typically available within 48–96 hours at JCI/NABH-accredited labs in India; 48–72 hours at DHA-licensed labs in Dubai/Abu Dhabi

• Treating surgeon reviews histopathology; patient counselled on findings. If margins are clear and base is benign/AK: no further surgical intervention required. If SCC with involved margins: re-excision or Mohs planning initiated before departure where feasible.

DAY 7–14 — SUTURE REMOVAL AND FIT-TO-FLY ASSESSMENT:

• Suture removal performed on Day 7 (face/scalp — high vascularity) or Day 10–14 (trunk/limbs — lower vascularity)

• Wound assessed for epithelialisation, absence of infection, and scar quality

• Fit-to-fly criteria: wound fully epithelialised, no active infection, no open areas, minimal swelling, and patient haemodynamically stable. For standard excision, this is typically achieved by Day 7–10.

• Scar management initiated: medical-grade silicone gel sheet (e.g., Mepiform, Dermatix) applied for 12 hours/day for 3–6 months; SPF 50+ sunscreen to the site mandatory for 12 months

• Final pre-departure consultation: discharge summary, histopathology report, emergency contact numbers, and follow-up instructions issued in patient's language

POST-RETURN HOME (WEEK 3 ONWARDS):

• Wound scar continues to mature over 6–18 months (erythema fades; scar softens)

• Follow-up dermoscopy/skin examination at 3, 6, and 12 months recommended — can be performed by local dermatologist using the GAF Healthcare discharge protocol

• For confirmed SCC base: structured surveillance per NCCN guidelines (3-monthly skin checks for 2 years; annual skin and nodal examination thereafter)

• Teleconsultation with treating surgeon available via the GAF Healthcare digital platform at no additional charge within the first 30 days post-discharge